Nilafustin (Anidulafungin)

Anidulafungin blocks the enzyme responsible for synthesising β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. Inhibiting this pathway weakens the wall, causing osmotic instability and cell death in susceptible Candida species while sparing human cells that lack this target.

The dosing regimen for Nilafustin is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and local guidelines. It is administered intravenously under medical supervision, and the exact dose and infusion rate are individualized for each patient.

Safety data for anidulafungin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Nilafustin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics where required) and any necessary import documentation.

Nilafustin belongs to the echinocandin class, similar to caspofungin and micafungin. Compared with azole antifungals, echinocandins have a lower risk of drug‑drug interactions and are effective against many azole‑resistant Candida strains. Within the class, anidulafungin has a long half‑life, allowing once‑daily dosing after a loading dose, and does not require routine therapeutic drug monitoring.

Nilafustin should be stored refrigerated at 2 °C to 8 °C. The vial must be kept in its original packaging, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used promptly according to the manufacturer’s instructions and discarded if not administered within the recommended time frame.

Nilafustin is supplied as a sterile powder for solution for injection. After reconstitution with the appropriate diluent, it is administered intravenously, typically over a one‑hour infusion. The infusion is performed by qualified healthcare personnel in a clinical setting, and the dose may be adjusted based on patient-specific factors.

The most serious adverse events associated with anidulafungin include severe hepatic injury, anaphylactic or severe hypersensitivity reactions, and rare but life‑threatening skin conditions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of liver dysfunction, rash, respiratory distress, or sudden hypotension during and after infusion.

Nilafustin is contraindicated in individuals with a known hypersensitivity to anidulafungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, as safety has not been established. Pediatric use is not approved, and the drug should be avoided in patients where alternative therapies are more appropriate.